gilead sciences annual report gilead financial highlights millions notes nongaap net income excluded stockbased compensation expense relating sfas r began expensing stockbased compensation january nongaap net income excluded makewhole payment related redemption million convertible senior debt gain related warrants eyetech pharmaceuticals inc acquired osi pharmaceuticals inc completed initial public offering nongaap net income excluded onetime tax provision benefit related qualified dividend distribution made american jobs creation act nongaap net income excluded impact iprd charges billion associated acquisitions corus august myogen november eunever latot millions emocni ten paagnon ssol emocni ten paag wolf hsac gnitarepo rehto arespeh emosibma esihcnarf vih millions eunever tcudorp millions ssol emocni ten gilead sciences annual report headquarters gilead sciences annual report gilead sciences inc lakeside drive foster city ca phone letter stockholders fax gilead hivaids hepatitis b c additional marketed products respiratory cardiopulmonary therapies gilead community vision corporate information financial highlights iieana front cover living hiv gilead sciences annual reportgilead sciences annual report gilead financial highlights millions notes nongaap net income excluded stockbased compensation expense relating sfas r began expensing stockbased compensation january nongaap net income excluded makewhole payment related redemption million convertible senior debt gain related warrants eyetech pharmaceuticals inc acquired osi pharmaceuticals inc completed initial public offering nongaap net income excluded onetime tax provision benefit related qualified dividend distribution made american jobs creation act nongaap net income excluded impact iprd charges billion associated acquisitions corus august myogen november eunever latot millions emocni ten paagnon ssol emocni ten paag wolf hsac gnitarepo rehto arespeh emosibma esihcnarf vih millions eunever tcudorp millions ssol emocni ten gilead sciences annual report headquarters gilead sciences annual report gilead sciences inc lakeside drive foster city ca phone letter stockholders fax gilead hivaids hepatitis b c additional marketed products respiratory cardiopulmonary therapies gilead community vision corporate information financial highlights iieana front cover living hiv gilead sciences annual reportthe commercial success marketed products provides us resources generate new clinical data defining profiles supports development new therapeutic advancements leveraged strong financial position broaden product portfolio better position company longterm growth bring new products clinical development goal remains improve lives patients worldwide suffering life threatening diseases marketed products product pipeline phase product indication partners candidate research preclinical ii iii new drug application atripla hivaids bristolmyers squibb company us canada ambrisentan efavirenz mgemtricitabine mg merck co inc developing world tenofovir disoproxil fumarate mg truvada hivaids japan tobacco inc japan aztreonam lysine inhalation emtricitabine tenofovir disoproxil fumarate viread hivaids japan tobacco inc japan tenofovir disoproxil fumarate tenofovir disoproxil fumarate emtriva hivaids japan tobacco inc japan darusentan emtricitabine hepsera chronic hepatitis b glaxosmithkline inc asia latin america gs adefovir dipivoxil integrase inhibitor ambisome severe fungal astellas pharma inc us canada gs amphotericin b liposome injection infections dainippon sumitomo pharma co ltd japan polymerase inhibitor tamiflu influenza b f hoffmannla roche ltd worldwide small molecule therapeutics oseltamivir phosphate macugen neovascular wet osi pharmaceuticals inc us small molecule therapeutics pegaptanib sodium injection agerelated macular pfizer inc outside us degeneration amd vistide cmv retinitisaids pfizer inc outside us inhaled therapeutics cidofovir injection flolan primary pulmonary glaxosmithkline inc outside us epoprostenol sodium injection hypertension mocotohpojuaraedwww ojuara ed egroj yb dna mocotohpeiruwww eiru retlaw yb yhpargotohp mocsutnemwww ainrofilac ogeid nas sutnem yb decudorp dna dengised pulmonary arterial hypertension cystic fibrosis chronic hepatitis b resistant hypertension hivaids hepatitis c viral infections cardiopulmonary respiratory infectionsgilead sciences annual report stockholders employees friends since founding company gilead focused developing delivering medications advance treatment lifethreatening diseases worldwide singular motivation achievements result progress traced many years time create foundation continued growth beyond gileads products partnerships generated market leadership hiv hepatitis b billion total revenues th influenza year marked th anniversary year pleased rapid growth continued first reported aids cases united states commercial success products impor course last five years gilead contributed tantly proud efforts deliver tremendous progress made treatment innovative therapeutics improving lives hivaids today hiv therapies critical compo patients suffering lifethreatening diseases nents mostprescribed highly active antiretroviral therapy haart regimens contributed infectious diseases particular focus overall success treatment paradigm helping efforts foundation business nearly greatly reduce pill burden backed years safety two decades year leveraged strong financial efficacy data viread truvada carved position broaden product portfolio beyond infec leadership positions among hiv treatments first tious diseases position company longterm complete haart combination oncedaily growth acquisitions corus pharma inc single tablet atripla quickly joined ranks since myogen inc investigational commercial us approval july hiv franchise products cornerstone new respiratory consists viread emtriva truvada atripla generated cardiopulmonary portfolio expanding ability billion product sales fulfill strategic objective developing commer cializing novel products deliver therapeutic advance ments physicians patients around world advancing therapeutics gilead sciences annual report nearly patients united states receiving antiretroviral therapy hiv infection approximately half taking one gilead hiv medications however potential growth remains approximately people diagnosed hiv yet started treatment another estimated hivinfected unaware status currently treatment hivpositive patients recom addition strong market growth seen tamiflu mended plasma hiv viral load exceeds product invented codeveloped partner copiesml cd cell counts f hoffmannla roche ltd roche one cellsmm many physicians virologists sold worldwide roche tamiflu initially developed believe earlier diagnosis initiation treatment treatment prevention seasonal flu may improve outcomes also significantly reduce also seen key component pandemic planning spread disease september us centers prepare potential spread avian flu virus disease control prevention cdc took first largely due corporate planning government stock step along path recommended routine voluntary piling roche generated record sales tamiflu resulting hiv screening healthcare settings individuals ages royalty revenue recognized gilead improving hiv testing diagnosis may help million raise awareness disease bring people enhanced product pipeline several drugs care potentially reduce rate new infections development could enhance hiv also continued grow hepatitis franchise hepatitis franchises currently novel integrase hepsera remains mostprescribed antiviral inhibitor gs development treatment treatment chronic hepatitis b united states hiv integrase inhibitors target different stage hiv despite increased competition market tenofovir replication cycle currently marketed classes disoproxil fumarate active agent viread drugs may combination antiretro phase iii clinical trials treatment chronic virals effectively prevent replication virus hepatitis b compound potential body particularly resistant virus also novel growth driver hepatitis franchise much compound early clinical development gs treat way hiv portfolio hepatitis c years front row left right james r meyers senior vice president commercial operations north america gregg h alton improving lives senior vice president general counsel william lee phd senior vice president research anthony caracciolo senior vice president manufacturing operations back row norbert w bischofberger phd executive vice president research development chief scientific officer john j toole md phd senior vice president clinical research kristen metza vice president human resources bruce montgomery md senior vice president head respiratory therapeutics john f milligan phd chief operating officer chief financial officer kevin young executive vice president commercial operations john c martin phd president chief executive officer taiyin yang phd senior vice president pharmaceutical development manufacturing gilead sciences annual report grown strong financial position enabled us leverage corporate partnerships build portfolio commercial products investigational compounds acquisi tions corus myogen added latestage clinical candidates pipeline providing near longterm revenue potential placing gilead excellent position enter respiratory cardiopulmonary markets completed acquisitions corus myogen believe experience registering commercial brands products worldwide began longterm growth created extraordi second half welcomed employees izing highly differentiated specialty products enable opening additional commercial operations europe nary product portfolio improving lives hun team gilead companies possessed latestage us build products successful respiratory lessen reliance distributors capture greater dreds thousands people unmet medical needs clinical drug candidates demonstrated potential cardiopulmonary portfolio provide founda revenue european union product sales expan innovation every aspect business enabled address significant unmet medical needs treat tion near longterm growth continue sion give us ability effectively control us develop bestinclass therapeutics ment respiratory cardiopulmonary diseases look additional opportunities broaden franchise launch commercialization products successfully commercialize worldwide remain augment existing pipeline important markets focused developing commercializing therapies acquisition corus august gained continue transform treatment paradigms phase iii drug candidate aztreonam lysine inhalation small molecule therapeutics constituting signifi recognize need enhance access hiv hiv hepatitis respiratory cardiopulmonary diseases potential treatment cystic fibrosisrelated lung cant portion development efforts november medications worldwide stepped efforts infections acquisition myogen november added made decision acquire raylo chemicals inc year extend availability resourcelimited would like thank employees contribution two promising drug candidates development assets germanybased specialty chemi parts world epidemic hit hardest achievements year team inspired portfolio ambrisentan treatment pulmonary cals company degussa ag years raylo end completed regulatory submissions individuals committed improving patients arterial hypertension darusentan treatment generated raw materials manufactured active viread nearly access program countries lives physicians primary customers resistant hypertension ambrisentan currently pharmaceutical ingredients api several antiviral reached nonexclusive license agreements quite simply gilead review us food drug administration fda compounds new edmonton alberta site help indian generic manufacturers produce distribute pleased accomplished year additionally part myogen acquisition gained ensure clinical commercial api supplies support generic versions viread resourcelimited countries look forward reporting progress commercial therapeutic flolan indicated ongoing small molecule development programs also established partnership merck co inc longterm intravenous treatment primary pulmo assist chemical development activities improve exist distribute atripla developing world addition nary hypertension myogens existing agreement ing commercial manufacturing processes advancing accesstm program continue glaxosmithkline inc gsk gained rights support access patients united states john c martin phd worldwide reach company continues grow market distribute flolan united states afford pay medications president chief executive officer increasingly focused commercialization c dna b sititapeh detekram lanoitidda dna yrotaripser ytinummoc eht ni daelig stcudorp seipareht yranomlupoidrac gilead sciences annual report among patients currently receiving antiretroviral treatment united states approxi mately percent first line treatment percent receiving secondline regimens percent receiving thirdline regimens beyond hivaids viread emtriva truvada atripla treatment hiv design hiv medicines goal favorable safety efficacy resistance profiles formulat ing tablets taken day products attained lead ership positions fight growing hiv epidemic drug plays integral role field combination therapy hiv treatment continue secure large growing share hiv market viread foundation hiv franchise viread atripla established us joint venture part combination therapy molecule form bristolmyers squibb company bms first kind tenofovir disoproxil fumarate also component field hiv medicine coformulate truvada truvada atripla continues increasing efavirenz single tablet result atripla use treatment patients varying stages first complete haart combination available hiv disease currently half treated hiv united states oncedaily single tablet treat patients united states taking tenofovir ment hiv atripla exhibited strong uptake july containing regimen year tenofovir surpassed us fda approval launch united states lamivudine widely prescribed hiv molecule expand number patients could benefit united states worldwide sales viread atripla together bms merck million share rights efavirenz europe submitted market ing authorisation application european union truvada fixeddose combination viread october approval anticipated second half emtriva truvada currently commonly pre addition completed separate agreement scribed backbone hiv combination therapy merck holds rights efavirenz resource united states accounting half hiv limited parts world help ensure access franchise sales growing uptake europe medication hiv epidemic hit hardest available countries helped contrib ute billion total sales ileana daughter united states hiv increasingly impacting communities color women hivpositive woman belonging largest fastest growing ethnic minority group united states ileana recognizes importance hivaids education outreach latino community sdiavih c dna b sititapeh detekram lanoitidda dna yrotaripser ytinummoc eht ni daelig stcudorp seipareht yranomlupoidrac gilead sciences annual report hivaids treatment regimens consist least three medications taken combination lower amount hiv viral load patients body result help increase number immune system cells hivaids ten years ago use potent antihiv drug combinations revolutionized aids care since viread introduced gileads antiretroviral therapies grown become cornerstone haart many patients helping transform hiv infection longterm treatable disease years introduction atripla united states pending approval european union signify landmark aids therapy first time hiv patients take complete haart regimen single oncedaily tablet early diagnosis critical order maximize haart availability longterm clinical data combination effectiveness extend survival hivpositive people regimens never important recent studies show many patients diagnosed design conduct clinical trials support use hiv infection advanced stage disease products demonstrate established safety treatment less effective tolerability profiles september us cdc recommended hiv test year reported data two longterm clinical ing become routine part medical care americans trials viread prescribed part aged us cdc believes routine hiv testing truvada atripla august reported may help identify estimated people week data study ongoing clinical trial united states realize infected comparing oncedaily regimen viread emtriva fore potentially reducing annual rate new infec efavirenz components atripla regimen tions earlier diagnosis treatment may significantly twicedaily combivir oncedaily efavirenz september extend lives diagnosed soon infection life reported longterm data study e expectancy hivpositive patients extended extension pivotal phase iii clinical trial data much years evaluated safety efficacy treatment viread lamivudine efavirenz five years hiv patients living longer potential patients diagnosed referred care isabelle ravaux md centre dinformation et de soins dimmunodficience humaine hpital de la conception marseilles france dr isabelle ravaux leading hiv treating physician hpital de la conception large city hospital southern france dr ravaux works serve needs varied patient population including migrants gaybisexual men many coinfected hiv hepatitis viruses hospital cares aids patients annually part local network clinics called assistance publique hpitaux de marseille aphm serves lowincome individuals sdiavih c dna b sititapeh detekram lanoitidda dna yrotaripser ytinummoc eht ni daelig stcudorp seipareht yranomlupoidrac gilead sciences annual report million people died aids worldwide highest number ever reported time period million people became newly infected hiv hiv therapies development hiv global community efforts key successfully combating hiv disrupt forty million people living hiv throughout world two replication body hiv replication involves thirds people living subsaharan africa need simplified effective number steps representing mechanism therapies treat hiv developing countries staggering improve lives potentially targeted drug haart therapy greater share global population suffering disease combines antiretrovirals least two differ continue efforts foster access drugs throughout world ent classes medications purpose disrupting hiv lifecycle different mechanism clinical data generated longterm safety efficacy even government nonprofit organizations headtohead studies become focal point industrybased initiatives improve access hiv treat halting spread virus destruction communications physicians worldwide helping ments year still estimated five million patients immune cells higher efficacy us differentiate products therapies people becoming infected hiv worldwide new combinations longer takes virus recognize need access hiv therapeutics prevention strategies urgently needed com mitted gaining understanding potential role mutate develop resistance therapy particularly developing countries limited resources viread truvada prevention transmis combat epidemic enhance reach sion hiv part commitment providing areas expanded gilead access program viread truvada cost use ongoing studies countries includes countries africa organized family health international us cdc caribbean many lowincome nations latin national institutes health thirdparty america southeast central asia partners additionally december granted program provide access viread truvada rights international partnership microbicides greatly reduced prices conrad develop manufacture proven better enable access therapy year granted efficacious distribute resourcelimited countries licensing technology transfer agreements india gel formulation tenofovir use microbicide based companies manufacturing distribution prevent transmission hiv generic versions viread developing world extend reach atripla also signed agreement merck distribution drug developing world sdiavih focused expanding upon successful hiv franchise addition novel drugs target different mechanisms within hiv replication cycle made progress year leading compound gs integrase inhibitor integrase inhibitors new important class hiv drugs may combination antiretrovirals elicit rapid reduction viral load february announced completion phase ii clinical trial gs boosted ritonavir positive safety efficacy data pre sented th conference retroviruses opportunistic infections design registrational studies underway sdiavih detekram lanoitidda dna yrotaripser ytinummoc eht ni daelig stcudorp seipareht yranomlupoidrac gilead sciences annual report hbv vaccine percent effective prevent ing children adults developing chronic hepatitis b effective person already infected virus vaccine available hepatitis c hepatitis b c viral infections caused hepatitis b c growing prevalence worldwide putting millions people risk developing lifethreatening liver disease cancer viruses lead development acute disease readily diagnosed many people contract viruses develop chronic infec tions go undetected years silent infections together lack awareness hepatitis b c transmitted significantly contribute spread diseases hepatitis b although effective vaccine available garner greater share growing hepatitis b prevent hepatitis b virus hbv infection two billion market currently studying tenofovir disoproxil people worldwide infected virus fumarate active ingredient viread treatment rising infection rate due part virulence hbv disease data generated hiv clinical trials times infectious hiv spread product led decision pursue additional exacerbated fact million people living indication compound studies tenofovir chronic lifelong hbv infections unknowingly disoproxil fumarate lowered amounts hepatitis virus passing others patients coinfected hiv hbv june completed enrollment two pivotal phase iii clinical trials available countries worldwide hepsera studies tenofovir disoproxil fumarate remains one leading drugs market treat chronic hepatitis b anticipate data chronic hepatitis b generating million pivotal studies end revenues approved us fda hepsera continues capture half total hepatitis c vaccine horizon prescription market hbv antivirals united states incidence hepatitis c worldwide growing unabated million individuals estimated globally estimated million people chronically living chronic hbv incidence disease infected hepatitis c virus hcv three four europe rising approximately nine million people million people newly infected year living chronic hbv infections sales growth continues applying expertise development european union particularly france greece italy antiviral drugs toward discovery new therapies turkey highest prevalence treat hepatitis c began clinical evaluation disease gsk markets hepsera countries outside front row left right julie winn md assistant director hepatology liver transplant f fred poordad md chief hepatology liver transplant middle row nonnucleoside hcv polymerase inhibitor gs kerstin newland rn martin briseno rn anush arakelyan back row ryan cabatbat nicholas n nissen md director hepatobiliary pancreatic surgery sandy leong gilead territories significant include hcvinfected individuals december rn shampa de phd center liver disease transplantation cedarssinai medical center provides highlevel expertise patients coping serious liverrelated illnesses china japan korea taiwan including viral hepatitis addition diagnosing treating complex medical conditions staff engaged cuttingedge research center liver disease transplantation participated hepsera pivotal clinical trials part ongoing tenofovir disoproxil fumarate clinical program c dna b sititapeh c dna b sititapeh dna yrotaripser ytinummoc eht ni daelig seipareht yranomlupoidrac gilead sciences annual report fiona palmer marketing joe baini general manager angela salamoussa marketing gileads operations australia responsible sales marketing clinical trial activities throughout australia new zealand australian team committed providing highest quality service customers commitment evident gileads commercial medical support products ambisome approved australia sdiavih royalty stream generated worldwide sales tamiflu exceeded million additional marketed products hiv hepatitis drugs significant revenue contributors gilead additional products continue generate revenue extend corporate brand proven treatments range infectious viral diseases ambisome tamiflu vistide collectively delivered solid financial results ambisome first approved europe years prevention common strains influenza b ago ambisome remains strong seller even face available pill liquid suspension form last new competition ambisome used treat systemic flu season doctors wrote prescriptions tamiflu fungal infections particularly immunocompromised antiviral flu treatment tamiflu also patients fungal infections increasingly common demonstrated effectiveness blocking replication hospital settings astellas pharma inc promotes hn virus known cause avian flu date sells ambisome united states canada dainippon countries begun stockpile tamiflu event sumitomo pharma co ltd markets ambisome japan influenza pandemic gilead retains exclusive marketing rights ambisome vistide marketed united states gilead throughout rest world ambisome available internationally pfizer inc vistide antiviral countries worldwide treatment cytomegalovirus retinitis aids tamiflu discovered gilead marketed worldwide patients year marked th anniversary roche tamiflu approved treatment products initial launch detekram lanoitidda stcudorp sdiavih c dna b sititapeh detekram lanoitidda ytinummoc eht ni daelig stcudorp gilead sciences annual report cystic fibrosis remains unmet medical need children suffered cf respiratory expected make first grade today aver age lifespan patient cardiopulmonary therapies cf years advancements treatments helping extend lives broadened focus beyond respiratory therapies infectious diseases acquisitions two specialty biopharmaceutical compa nies corus myogen work ing address diseases represent areas significant unmet medical need cystic fibrosis cf impacts lives people families promising latestage product candidates worldwide known cure inherited chronic disease affects along approved drug treat lungs digestive tract acquisition corus enhances development ment primary pulmonary hypertension portfolio compounds treat respiratory infections including one latestage gained acquisitions form candidate potential treatment cystic fibrosisrelated lung infections basis new respiratory cardiopul monary business believe com pulmonary infection gramnegative bacteria particu lysine inhalation granted orphan drug status pounds enable us capture signifi larly pulmonary pseudomonas aeruginosa p aeruginosa united states european union cant share market treatment represents single greatest cause illness death two pivotal phase iii clinical studies initiated among people cf developed scientists corus cystic fibrosisrelated lung infections determine safety efficacy aztreonam lysine aztreonam lysine inhalation antibiotic activity inhalation treating cf patients p aeruginosa pulmonary arterial hypertension resistant gramnegative bacteria including p aeruginosa infections late announced positive results hypertension related diseases drug delivered novel inhalation device placebocontrolled aircf study believe eflow electronic nebulizer developed pari aztreonam lysine inhalation granted marketing gmbh pari also contributed development approval potential become important new optimization drug formulation aztreonam lysine cf treatment option efficient fast delivery eflow aztreonam dna yrotaripser seipareht yranomlupoidrac jade living cystic fibrosis thanks important advancements treatment cystic fibrosis jade sidelines every football game year cheering home team sdiavih c dna b sititapeh detekram lanoitidda ytinummoc eht ni daelig stcudorp gilead sciences annual report pulmonary arterial hyper tension debilitating disease affects people worldwide twice many cases reported women men approximately percent pah patients succumb disease within five years diagnosis cardiopulmonary therapies endothelin small peptide hormone believed play critical role regulation blood flow cell division elevated endothelin blood levels associated several cardiovascular disease conditions including pulmonary arterial hypertension pah resistant hypertension two endothelin receptor antagonists ambrisentan treatment pah darusentan treatment resistant hypertension foundation gileads cardiopulmonary development portfolio resulted acquisition myogen current therapeutic options pah limited acquisition myogen also gained remains unmet need safe effective new commercialization rights flolan united states treatments december submitted new developed gsk flolan synthetic chemical similar drug application nda us fda ambrisentan prostacyclin naturally occurring chemical body treatment pah february us fda helps regulate size diameter blood vessels granted priority review nda giving ambrisentan approved longterm intravenous treat estimated sixmonth review compound ment primary pulmonary hypertension product granted orphan drug status treatment pah provided important opportunity usbased united states european union approved specialty sales team gain experience selling products believe ambrisentan profile become field pah endothelin receptor antagonist choice treat march agreement myogen gsk ment pah holds rights commercialize ambrisentan terri another candidate development darusentan tories outside united states gsk currently currently evaluated phase iii clinical trials markets flolan potential treatment resistant hypertension lewis j rubin md professor medicine pulmonary critical care university california san diego dr rubin involved basic research clinical investigation direct care patients pulmonary vascular diseases twenty years serves steering committee pivotal trials ambrisentan treatment pulmonary arterial hypertension dna yrotaripser seipareht yranomlupoidrac sdiavih c dna b sititapeh detekram lanoitidda dna yrotaripser stcudorp seipareht yranomlupoidrac gilead sciences annual report ytinummoc eht ni daelig gilead community mission develop commercialize novel pipeline promising latestage products products deliver therapeutic advancements believe making significant progress toward improve lives patients around world goal commitment extends beyond products currently market benefiting products offer broader communities hundreds thousands people worldwide live work carol reagan accounting san dimas california global camps africa gilead foundationfunded program offers camp experience ernie rodriguez gilead community liaison chicago illinois kevin stapleton phd respiratory pharmaceutical development seattle washington children affected hivaids goal creating healthy vision future us advancing access program provides access certain gilead community partnerships key component patient education employees part implementing mission established gilead foundation nonprofit philanthropic orga medications people obtain reimbursement afford programs participate grassroots programs focused every day gilead employees make time participate annual patient nization seeks improve access healthcare people around pay since programs inception patients driving awareness hiv hbv encouraging patients take community events local walks marathons bicycle rides raise world gilead foundation funded organizations received gilead therapies active role treatment also work closely patient advocacy funds nonprofit healthcare organizations addition provide unre support hiv education healthcare training infrastructure treatment groups better understand address needs concerns stricted educational grants support efforts thirdparty patient organi programs resourcelimited countries well disease awareness zations providing important services local patient communities education programs underserved communities united states gilead sciences annual report senotselim daelig gilead grown markedly years since inception successful identification develop ment drugs attack hiv different stages william delaney phd biology foster city california viruss replication established gilead leader therapeutic category resulting financial suc cess enabled us fuel development new therapies hiv hepatitis expand prod uct portfolio include novel therapies treat chronic respiratory cardiopulmonary diseases contin lloyd e bailey md attending physician spellman center hiv related disorders st vincents midtown hospital new york ued financial corporate growth change remain committed developing commercializing innovative therapeutics treat life threatening diseases worldwide gilead patients families oanh living hepatitis b vision gilead ambisome inlicensed vistide nexstar acquired viread hepsera triangle truvada atripla approved founded approved nucleotides approved establishment approved approved acquired approved corus acquired iocbrega european emtriva macugen operations raylo acquired approved approved tamiflu approved myogen acquired corporate information board directors executive committee scientific advisory board corporate secretary annual meeting james denny john c martin phd bernard wagner md gregg h alton annual meeting chairman gilead sciences president chairperson senior vice president stockholders held board directors chief executive officer new york university general counsel wednesday medical center may westin paul berg phd norbert w bischofberger phd corporate counsel san francisco airport hotel nobel prize winner chemistry executive vice president jacqueline k barton phd cooley godward kronish llp cahill professor emeritus research development california institute palo alto california transfer agent registrar stanford university chief scientific officer technology communications concerning medical center independent registered stock transfer requirements john f milligan phd francis v chisari md public accountants lost certificates changes john f cogan phd chief operating officer scripps research institute senior fellow hoover chief financial officer ernst young llp address directed institution stanford university peter b dervan phd palo alto california transfer agent kevin young california institute mellon investor services llc etienne f davignon executive vice president technology corporate headquarters po box minister state commercial operations gilead sciences inc south hackensack nj vicechairman sueztractebel joel r huff phd lakeside drive usa gregg h alton foster city ca carla hills senior vice president howard jaffe md usa wwwmelloninvestorcom chair chief executive general counsel gilead foundation officer hills company equal opportunity employer international consultants anthony caracciolo paul e klotman md wwwgileadcom gilead sciences proud senior vice president mt sinai medical center equal opportunity employer john w madigan manufacturing operations stockholder inquiries extends employment retired chairman mary e klotman md inquiries stockholders men women cultur chief executive officer william lee phd mt sinai medical center potential investors ally diverse backgrounds tribune company senior vice president research regarding company environment respects john w mellors md always welcome individual differences john c martin phd james r meyers university pittsburgh receive prompt response recognizes employee president chief executive senior vice president school medicine please direct requests integral member officer gilead sciences commercial operations information company workforce north america eugene r schiff md facp reflects values gordon e moore phd frcp macg investor relations celebrates individuals chairman emeritus bruce montgomery md university miami gilead sciences inc make growing team intel corporation senior vice president head school medicine lakeside drive respiratory therapeutics foster city ca nicholas g moore robert schooley md usa retired global chairman john j toole md phd university california phone pricewaterhousecoopers senior vice president san diego clinical research fax gayle edlund wilson richard j whitley md director education financing taiyin yang phd university alabama information regarding foundation california senior vice president birmingham gilead also available ralph parsons foundation pharmaceutical development wwwgileadcom manufacturing director emeritus gilead sciences board directors kristen metza stock listing george p shultz phd vice president gilead common stock traded distinguished fellow hoover human resources nasdaq global select institution stanford university stock market nasdaq symbol gildgilead sciences annual report gilead financial highlights millions notes nongaap net income excluded stockbased compensation expense relating sfas r began expensing stockbased compensation january nongaap net income excluded makewhole payment related redemption million convertible senior debt gain related warrants eyetech pharmaceuticals inc acquired osi pharmaceuticals inc completed initial public offering nongaap net income excluded onetime tax provision benefit related qualified dividend distribution made american jobs creation act nongaap net income excluded impact iprd charges billion associated acquisitions corus august myogen november eunever latot millions emocni ten paagnon ssol emocni ten paag wolf hsac gnitarepo rehto arespeh emosibma esihcnarf vih millions eunever tcudorp millions ssol emocni ten gilead sciences annual report headquarters gilead sciences annual report gilead sciences inc lakeside drive foster city ca phone letter stockholders fax gilead hivaids hepatitis b c additional marketed products respiratory cardiopulmonary therapies gilead community vision corporate information financial highlights iieana front cover living hiv gilead sciences annual reportgilead sciences annual report gilead financial highlights millions notes nongaap net income excluded stockbased compensation expense relating sfas r began expensing stockbased compensation january nongaap net income excluded makewhole payment related redemption million convertible senior debt gain related warrants eyetech pharmaceuticals inc acquired osi pharmaceuticals inc completed initial public offering nongaap net income excluded onetime tax provision benefit related qualified dividend distribution made american jobs creation act nongaap net income excluded impact iprd charges billion associated acquisitions corus august myogen november eunever latot millions emocni ten paagnon ssol emocni ten paag wolf hsac gnitarepo rehto arespeh emosibma esihcnarf vih millions eunever tcudorp millions ssol emocni ten gilead sciences annual report headquarters gilead sciences annual report gilead sciences inc lakeside drive foster city ca phone letter stockholders fax gilead hivaids hepatitis b c additional marketed products respiratory cardiopulmonary therapies gilead community vision corporate information financial highlights iieana front cover living hiv gilead sciences annual report